Applied Therapeutics reports Q1 EPS (67c), consensus (16c)

Expects cash and cash equivalents will fund the business into 2026. Reports Q1 revenue $190K, consensus $3.33M. “Preparations are underway for the potential approval and commercial launch of govorestat for the treatment of Classic Galactosemia in the US and EU, following the significant regulatory progress we have already made in 2024,” said CEO Shoshana Shendelman. “We are also discussing a potential NDA submission for SORD Deficiency with the Neurology Division at FDA, further advancing our objective of bringing first ever treatment to patients with rare diseases.”